Steeghs EMP, Gelderblom H, Ho VKY, Voorham QJM, Willems SM, Grünberg K, Ligtenberg MJL, PATH consortium. Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice. Gastric Cancer. 2021;24(5):990–1002. https://doi.org/10.1007/s10120-021-01190-9.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Zeng C, Zhu L, Jia X, Pang Y, Li Z, Lu X, Xie F, Duan L, Wang Y. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors. Gastric Cancer. 2020;23(5):837–47. https://doi.org/10.1007/s10120-020-01069-1.

CAS  Article  PubMed  Google Scholar 

Yoon H, Tang CM, Banerjee S, Yebra M, Noh S, Burgoyne AM, et al. Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene. 2021;40:1957–73.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Chen Y, Dong X, Wang Q, Liu Z, Dong X, Shi S, et al. Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia. Front Pharmacol. 2020;11:569843.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Boichuk S, Galembikova A, Mikheeva E, Bikinieva F, Aukhadieva A, Dunaev P, et al. Inhibition of FGF2-mediated signaling in GIST-promising approach for overcoming resistance to imatinib. Cancers (Basel). 2020;12:1674.

CAS  Article  Google Scholar 

Proudman D, Miller A, Nellesen D, Gomes A, Mankoski R, Norregaard C, et al. Financial implications of avapritinib for treatment of unresectable gastrointestinal stromal tumors in patients with a PDGFRA Exon 18 variant or after 3 previous therapies in a hypothetical US health plan. JAMA Netw Open. 2020;3:e2025866.

PubMed  PubMed Central  Article  Google Scholar 

Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Narjoz C, Favre A, McMullen J, Kiehl P, Montemurro M, Figg WD, et al. Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance. PLoS ONE. 2014;9:e95532.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Théou N, Gil S, Devocelle A, Julié C, Lavergne-Slove A, Beauchet A, et al. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res. 2005;11:7593–8.

PubMed  Article  CAS  Google Scholar 

Zhang Q, Li Z, Xu K, Qian Y, Chen M, Sun L, et al. Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor. Scand J Gastroenterol. 2019;54:220–6.

CAS  PubMed  Article  Google Scholar 

Kumar V, Singh P, Gupta SK, Ali V, Verma M. Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. Mol Cell Biochem. 2022. https://doi.org/10.1007/s11010-022-04376-6.

Article  PubMed  PubMed Central  Google Scholar 

Wang Q, Jiang ZP, Zeng J, Zhu Y, Cai HL, Xiang DX, et al. Effects of trough concentration and solute carrier polymorphisms on imatinib efficacy in Chinese patients with chronic myeloid leukemia. J Pharm Pharm Sci. 2020;2:1–9.

Article  Google Scholar 

Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, et al. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019;575:229–33.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Llopis B, Robidou P, Tissot N, Pinna B, Gougis P, Aubart FC, et al. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. J Pharm Biomed Anal. 2021;197:113968.

CAS  PubMed  Article  Google Scholar 

Rutkowski P, Ziętek M, Cybulska-Stopa B, Streb J, Głuszek S, Jankowski M, et al. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice. Eur J Surg Oncol. 2021;47:1191–5.

PubMed  Article  Google Scholar 

Tartaggia S, Meneghello A, Bellotto O, Poetto AS, Zanchetta M, Posocco B, et al. An SPR investigation into the therapeutic drug monitoring of the anticancer drug imatinib with selective aptamers operating in human plasma. Analyst. 2021;146:1714–24.

CAS  PubMed  Article  Google Scholar 

Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993. https://doi.org/10.1016/j.ctrv.2020.101993.

CAS  Article  PubMed  Google Scholar 

Elseud YA, Shaaban A, Mohanty A, Albarrak J. Safety and tolerability of regorafenib: a real-life experience. J Gastrointest Cancer. 2021. https://doi.org/10.1007/s12029-020-00570-1.

Article  PubMed  Google Scholar 

Chang YR, Huang WK, Wang SY, Wu CE, Chen JS, Yeh CN. A nomogram predicting progression free survival in patients with gastrointestinal stromal tumor receiving sunitinib: incorporating pre-treatment and post-treatment parameters. Cancers (Basel). 2021;13(11):2587. https://doi.org/10.3390/cancers13112587.

CAS  Article  Google Scholar 

Lu X, Pang Y, Cao H, Liu X, Tu L, Shen Y, Jia X, Lee JC, Wang Y. Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors. Cancer Res. 2021;81(9):2481–94. https://doi.org/10.1158/0008-5472.CAN-20-3580.

CAS  Article  PubMed  Google Scholar 

Grunewald S, Klug LR, Mühlenberg T, Lategahn J, Falkenhorst J, Town A, Ehrt C, Wardelmann E, Hartmann W, Schildhaus HU, Treckmann J, Fletcher JA, Jung S, Czodrowski P, Miller S, Schmidt-Kittler O, Rauh D, Heinrich MC, Bauer S. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 2021;11(1):108–25. https://doi.org/10.1158/2159-8290.CD-20-0487.

CAS  Article  PubMed  Google Scholar 

Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D’Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, George S, von Mehren M. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923–34. https://doi.org/10.1016/S1470-2045(20)30168-6.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Carriot N, Paix B, Greff S, Viguier B, Briand JF, Culioli G. Integration of LC/MS-based molecular networking and classical phytochemical approach allows in-depth annotation of the metabolome of non-model organisms—the case study of the brown seaweed Taonia atomaria. Talanta. 2021;225:121925.

CAS  PubMed  Article  Google Scholar 

Nigam SK. The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol. 2018;6(58):663–87. https://doi.org/10.1146/annurev-pharmtox-010617-052713.

CAS  Article  Google Scholar 

Brosseau N, Ramotar D. The human organic cation transporter OCT1 and its role as a target for drug responses. Drug Metab Rev. 2019;51:389–407.

CAS  PubMed  Article  Google Scholar 

Morse BL, Kolur A, Hudson LR, Hogan AT, Chen LH, Brackman RM, et al. Pharmacokinetics of organic cation transporter 1 (OCT1) substrates in Oct1/2 knockout mice and species difference in hepatic OCT1-mediated uptake. Drug Metab Dispos. 2020;48:93–105.

CAS  PubMed  Article  Google Scholar 

Chang HH, Hsueh YS, Cheng YW, Ou HT, Wu MH. Association between polymorphisms of OCT1 and metabolic response to metformin in women with polycystic ovary syndrome. Int J Mol Sci. 2019;20:1720.

CAS  PubMed Central  Article  Google Scholar 

Wang J, Lu L, Kok CH, Saunders VA, Goyne JM, Dang P, Leclercq TM, Hughes TP, White DL. Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica. 2017;102(5):843–53. https://doi.org/10.3324/haematol.2016.153270.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Xinwei D, Gang J, Songtao M, Yan C. Simultaneous determine of imatinib myslate and its metabolites in human plasma by two-dimensional liquid chromatography: a methodological study. J Cancer Control Treat. 2021;34(10):919–26.

Google Scholar 

Wang Q, Jiang ZP, Zeng J, Zhu Y, Cai HL, Xiang DX, et al. Effects of trough concentration and solute carrier polymorphisms on imatinib efficacy in chinese patients with chronic myeloid leukemia. J Pharm Pharm Sci. 2020;23:1–9.

PubMed  Article  Google Scholar 

Chen W, Kuang Y, Qiu HB, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y, Meng F, Fletcher JA, Ou WB. Dual targeting of insulin receptor and KIT in imatinib-resistant gastrointestinal stromal tumors. Cancer Res. 2017;77(18):5107–17. https://doi.org/10.1158/0008-5472.CAN-17-0917.

CAS  Article  PubMed  Google Scholar 

Zhou Y, Chen J, Weng X, Lin G, Huang Z, Shui H. Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate. Oncol Lett. 2018;15(5):7589–94. https://doi.org/10.3892/ol.2018.8283.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Chen K, Ren Q, Han XR, Zhang XN, Wei B, Bai XZ. Imatinib mesylate induces mitochondria-dependent apoptosis and inhibits invasion of human pigmented villonodular synovitis fibroblast-like synovial cells. Oncol Rep. 2016;35(1):197–204. https://doi.org/10.3892/or.2015.4350.

CAS  Article  PubMed  Google Scholar 

Su B, Huang T, Jin Y, Yin H, Qiu H, Yuan X. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways. Gastric Cancer. 2021;24(2):352–67. https://doi.org/10.1007/s10120-020-01126-9.

CAS  Article  PubMed  Google Scholar 

Vetter TR. Fundamentals of research data and variables: the devil is in the details. Anesth Analg. 2017;125:1375–80.